Dr. Zambidis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1800 Orleans Street
Bloomberg 11N
Baltimore, MD 21287Phone+1 410-955-8751Fax+1 410-614-1802
Education & Training
Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 2001 - 2004
Washington University/B-JH/SLCH ConsortiumResidency, Pediatrics, 1998 - 2001
University of Rochester School of Medicine and DentistryClass of 1998
Certifications & Licensure
MD State Medical License 2001 - 2025
American Board of Pediatrics Pediatrics
Clinical Trials
- LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis Start of enrollment: 2016 Nov 02
Roles: Contact
- Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis Start of enrollment: 2021 Jul 13
Roles: Contact, Principal Investigator
- Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders Start of enrollment: 2021 Apr 19
Roles: Contact
Publications & Presentations
PubMed
- 5 citationsAntiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II intervent...Michael D Keller, Patrick J Hanley, Yueh-Yun Chi, Paibel Aguayo-Hiraldo, Christopher C Dvorak
Nature Communications. 2024-04-18 - 1 citationsHarnessing bioengineered myeloid progenitors for precision immunotherapies.Willem Buys, Elias T Zambidis
NPJ Regenerative Medicine. 2023-12-12 - 1 citationsRosai-Dorfman Disease Presenting as Massive Mediastinal Lymphadenopathy in an Elderly Man.Yash M Maniar, Christian F Meyer, Michelle Sharp, Elias T Zambidis, Nada A I Qaysi
Annals of Internal Medicine. Clinical Cases. 2022-10-01
Press Mentions
Use of a Response-Adapted Ruxolitinib-Containing Regimen for the Treatment of Hemophagocytic LymphohistiocytosisSeptember 16th, 2020- Use of a Response-Adapted Ruxolitinib-Containing Regimen for the Treatment of Hemophagocytic LymphohistiocytosisJuly 27th, 2023
Grant Support
- Embryonic vascular stem-progenitors for treatment of ischemic retinopathiesJOHNS HOPKINS UNIVERSITY2021–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
